Inotuzumab Ozogamicin Versus Standard Care for Acute Lymphoblastic Leukemia

BACKGROUND: Inotuzumab ozogamicin, an anti-CD22 antibody conjugated to calicheamicin, is active in acute lymphoblastic leukemia. METHODS: In this phase 3 trial, adults with relapsed/refractory acute lymphoblastic leukemia were randomized to inotuzumab ozogamicin or standard intensive chemotherapy. P...

पूर्ण विवरण

में बचाया:
ग्रंथसूची विवरण
में प्रकाशित:N Engl J Med
मुख्य लेखकों: Kantarjian, Hagop M., DeAngelo, Daniel J., Stelljes, Matthias, Martinelli, Giovanni, Liedtke, Michaela, Stock, Wendy, Gökbuget, Nicola, O’Brien, Susan, Wang, Kongming, Wang, Tao, Paccagnella, M. Luisa, Sleight, Barbara, Vandendries, Erik, Advani, Anjali S.
स्वरूप: Artigo
भाषा:Inglês
प्रकाशित: 2016
विषय:
Article
ऑनलाइन पहुंच:https://ncbi.nlm.nih.gov/pmc/articles/PMC5594743/
https://ncbi.nlm.nih.gov/pubmed/27292104
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1056/NEJMoa1509277
टैग : टैग जोड़ें
कोई टैग नहीं, इस रिकॉर्ड को टैग करने वाले पहले व्यक्ति बनें!

समान संसाधन